A5061988331- Pulmonary Hypertension Research and Treatments
- Venous Thromboembolism Diagnosis and Management
- Transplantation: Methods and Outcomes
- Acute Myocardial Infarction Research
- COVID-19 Clinical Research Studies
- Vascular Anomalies and Treatments
- Atrial Fibrillation Management and Outcomes
- Mechanical Circulatory Support Devices
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiovascular Function and Risk Factors
- SARS-CoV-2 and COVID-19 Research
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Issues in Pregnancy
- Central Venous Catheters and Hemodialysis
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Arrest and Resuscitation
- Tracheal and airway disorders
- Radiation Dose and Imaging
- Smoking Behavior and Cessation
- Long-Term Effects of COVID-19
- Liver Disease and Transplantation
- Trauma Management and Diagnosis
- Cardiac Arrhythmias and Treatments
- Lipoproteins and Cardiovascular Health
- Heart Failure Treatment and Management
Masih Daneshvari Hospital
2016-2025
Shahid Beheshti University of Medical Sciences
2016-2025
Shahid Beheshti University
2009-2022
Shaheed Rajaei Cardiovascular Medical and Research Center
2022
Tobacco Research Institute
2007-2012
Cell Medica (Switzerland)
2011
GTx (United States)
2011
Day General Hospital
2009
Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis.To evaluate effects intermediate-dose vs standard-dose prophylactic anticoagulation among COVID-19 admitted intensive care unit (ICU).Multicenter randomized trial a 2 × factorial design performed 10 academic centers Iran comparing (first hypothesis) and statin therapy matching placebo (second hypothesis; not this article) adult ICU Patients...
Microvascular and macrovascular thrombotic events are among the hallmarks of coronavirus disease 2019 (COVID-19). Furthermore, exuberant immune response is considered an important driver pulmonary extrapulmonary manifestations COVID-19. The optimal management strategy to prevent thrombosis in critically-ill patients with COVID-19 remains unknown.
Abstract Background Thrombotic complications are considered among the main extrapulmonary manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration prophylactic antithrombotic therapy in these patients remain unknown. Methods This article reports final (90-day) results Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) study. Patients COVID-19 admitted to...
Abstract Objective To assess the effect of statin treatment versus placebo on clinical outcomes in patients with covid-19 admitted to intensive care unit (ICU). Design INSPIRATION/INSPIRATION-S was a multicenter, randomized controlled trial 2×2 factorial design. Results for anticoagulation randomization have been reported previously. double blind atorvastatin are here. Setting 11 hospitals Iran. Participants Adults aged ≥18 years ICU. Intervention Atorvastatin 20 mg orally once daily...
Abstract SARS‐CoV‐2 vaccines provide a safe solution with major impact on reducing the spread of virus and mild side effects. Research has shown rare cases myocarditis after mRNA vaccines. This study presents 29‐year‐old male chest pain 48 h receiving rAd26 rAd5 vector‐based COVID‐19 vaccine (Sputnik V vaccine). The electrocardiogram revealed ST‐segment elevation. Also, laboratory screening was remarkable for elevated cardiac Troponin‐I level, leukocytosis; echocardiography depicted severe...
Introduction The global coronavirus disease 2019 (COVID-19) pandemic necessitated urgent vaccine development, raising concerns about potential adverse events (AEs). Methods In this prospective cohort study, conducted from February 2021 to December 2022, all individuals across Iran who received any COVID-19 dose and reported were investigated. Our aim was evaluate these AEs based on the types, patients’ age types of AES, provide a comprehensive analysis. Results Iran, 155 million doses...
The chronic stimulation of β-adrenergic receptors plays a crucial role in cardiac hypertrophy and its progression to heart failure. In signaling, addition the well-established classical pathway, Gs/AC/cAMP/PKA, activation non-classical pathways such as Gi/PI3K/Akt/GSK3β Gi/Ras/Raf/MEK/ERK contribute hypertrophy. signaling network β-adrenergic-induced is very complex not fully understood. So, we use computational approach investigate dynamic response contribution mediators proposed model...
The present study is the premier clinical attempt to scrutinize practicability of prophylactic fibrinogen infusion in patients undergoing heart transplantation (HT). A total 67 consecutive who had undergone HT between January 2012 and December 2014 were assessed. After exclusion some patients, 23 given preoperative 2 g concentrate over a period 15 minutes after termination cardiopulmonary bypass pump complete reversal heparin, 30 not given. Some laboratories measured before general...
Background: Remdesivir is effective against SARS-Cov-2 with little evidence of its adverse effect on the cardiac system. The aim present study investigating incidence bradycardia in COVID-19 patients treated Remdesivir. Methods: This prospective longitudinal was conducted a tertiary center for therapy. objectives were to investigate sinus bradycardia, and also association between their demographics, underlying diseases, disease severity developing Results: Of 177 patients, 44% male. mean...
Ca2+ is an important mediator in the β-adrenergic-induced cardiac hypertrophy. The β-adrenergic stimulation alters transient characteristics including its oscillation frequency, diastolic and systolic levels which lead to CaN activation subsequent NFAT-dependent hypertrophic genes transcription. Moreover, alterations PKA GSK3β kinase activities both cytosol nucleus regulate NFAT nuclear translocation contribute response. Due complex nature of CaN/NFAT signaling cells, we use a computational...
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by the obstruction of main artery due to thrombosis and vascular remodeling. Regarding need for anticoagulant therapy in CTEPH patients, this study aimed compare rivaroxaban with warfarin terms its efficacy safety patients undergoing endarterectomy surgery. The was a parallel clinical trial who underwent following CTEPH. A total 96 were randomly selected assigned two groups: warfarin-treated (control) rivaroxaban-treated...
Background In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a nonsignificant 16% reduction in 30-day composite of venous/arterial thrombosis or death intensive care unit (ICU) patients COVID-19. Thrombo-inflammatory response coronavirus disease 2019 (COVID-19) may last beyond first 30 days. Methods This article reports effects 20 mg daily on 90-day clinical and functional outcomes from INSPIRATION-S, double-blind multicenter randomized trial adult ICU The main...
This study performed at the National Research Institute of Tuberculosis and Lung Disease, Tehran, Iran, aimed to evaluate effect concomitant pulmonary hypertension on outcome tuberculosis.New cases tuberculosis were recruited for study. Pulmonary was defined as systolic arterial pressure ≥ 35 mm Hg estimated by transthoracic Doppler echocardiography. We assessed relationship between mortality during six-month treatment tuberculosis.Of 777 new tuberculosis, 74 (9.5%) had Hg. Ten them (13.5%)...